Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder

Phase 4

Withdrawn

• Conditions: Major Depressive Disorder
• Interventions: Drug: Effexor XR; Other: Effexor XR discontinue

• Registration Number: NCT00878748
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an 8-week acute treatment and a 6-month continuation treatment phases. The study will also collect data on the prevalence and pattern of co-morbid anxiety and somatic symptoms and their impact on the recurrence of depression.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04
• Study First Submitted: 2009-04-08
• Study First Submitted QC: 2009-04-08
• Study First Posted: 2009-04-09
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-17
• Last Update Posted: 2021-08-20

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A	Effexor XR	Effexor XR
B	Effexor XR discontinue	Effexor XR discontinue

Primary Outcome Measures

Name	Time	Method
time from entering maintenance phase to recurrence of major depression	12 months

Secondary Outcome Measures

Name	Time	Method
Patient Health Questionnaire(PHQ-15),Clinical Global Impressions(CGI),Visual Analogue Scale(VAS),Short Form Health Survey(SF-36)	12 months